Pfizer Inc. $PFE Stock Holdings Increased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,023,011 shares of the biopharmaceutical company’s stock after purchasing an additional 91,444 shares during the period. Rakuten Investment Management Inc.’s holdings in Pfizer were worth $29,381,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Retirement Wealth Solutions LLC grew its position in shares of Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 509 shares during the period. Keb Asset Management LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $26,000. Field & Main Bank acquired a new stake in Pfizer during the 2nd quarter worth approximately $27,000. Bullseye Investment Management LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $28,000. Finally, Timbuktu Capital Management LLC bought a new position in Pfizer in the second quarter valued at approximately $29,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat earnings and revenue expectations, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its full-year revenue guidance to $62 billion–$64 billion, citing strong performance and momentum in newer and acquired medicines. Pfizer lifts FY26 guidance
• Positive Sentiment: Growth is broadening beyond COVID products: launched and acquired medicines grew 32%, with Eliquis, Padcev, Vyndaqel, Nurtec and Lorbrena among the products highlighted. Pfizer also cited progress in its obesity and oncology programs. Pfizer’s product growth
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. Her experience may support continuity in financial planning and capital allocation, though the appointment alone does not change the company’s outlook. Pfizer appoints Cecile Guegan CFO
• Negative Sentiment: Quarterly revenue was essentially flat year over year as COVID-related demand continued to fall: Paxlovid sales dropped 63% and Comirnaty sales declined 29%. The ongoing transition away from pandemic products leaves investors focused on whether newer medicines can offset those declines. Pfizer Q3 product sales
• Negative Sentiment: Despite the earnings beat and raised guidance, the stock eased. Investor caution may reflect expectations already embedded in the shares and uncertainty about the longer-term payoff from Pfizer’s acquisitions, pipeline and efforts to address upcoming patent expirations. Pfizer’s growth test ahead

Pfizer Trading Down 2.3%

NYSE:PFE opened at $29.98 on Wednesday. The company has a market cap of $170.85 billion, a P/E ratio of 39.44, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $31.06. The business has a 50 day moving average price of $28.64 and a two-hundred day moving average price of $26.84. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The company had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s revenue was down .4% compared to the same quarter last year. During the same period last year, the company earned $0.87 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.7%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. BMO Capital Markets reduced their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. JPMorgan Chase & Co. upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Finally, Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Five equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.65.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.